LAURUSLABS

- Q2FY26 Quarterly Result Announced for Laurus Labs Ltd.

Q2FY26 Quarterly Result Announced for Laurus Labs Ltd. -

Pharmaceuticals company Laurus Labs announced Q2FY26 results Revenue: Rs 1,653 crore compared to Rs 1,224 crore during Q2FY25, up 35%. EBITDA: Rs 429 crore compared to Rs 182 crore during Q2FY25, up 136%. EBITDA Margin: 26.0% for Q2FY26. PBT: Rs 270 crore compared to Rs 23 crore during Q2FY25, up 1,074%. PAT: Rs 195 crore compared to Rs 20 crore during Q2FY25, up 875%. Satyanarayana Chava, Founder & Chief Executive Officer, said: “We continue to maintain leadership position in ARVs and make encouraging progress in delivering important clinical and commercial programs. Our Q2 reflects on-going expansion of CDMO business, supported by sustained growth in Generics. Earlier this quarter we announced land allocation from Andhra government and proposed investments to support future business expansion, augmenting our offerings across manufacturing scale and new technologies. We also made strategic investment of USD 2 million in Aarvik Therapeutics to have access to novel Antibody-drug conjugates (ADC) technology and pipeline aimed at accelerating our integrated ADC services. I have increasing confidence that our R&D driven commercial strategy will continue to generate long-term value for our stakeholders.” All this is for information. This is not a buy/sell recommendation. Thank you, Technofunda24